Sheng Feng

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 5

Top Topics

Pulmonary Artery

Hepatitis B Virus

Top Venues

Drug design, development and therapy

Antimicrobial agents and chemotherapy

Clinical and translational science

Journal of clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Qian Chen, Chengyin Yu, Qingqing Wu, Rong Song, Ye Liu, Sheng Feng, Chen Yu, Jingying Jia
Evaluation of Drug-Drug Interaction Between Henagliflozin and Hydrochlorothiazide in Healthy Chinese Volunteers. Drug design, development and therapy 18 (2024)
Qian Chen, Chengyin Yu, Qingqing Wu, Rong Song, Ye Liu, Sheng Feng, Chen Yu, Jingying Jia
Evaluation of Drug-Drug Interaction Between Henagliflozin and Hydrochlorothiazide in Healthy Chinese Volunteers. Drug design, development and therapy 18 (2024)
Sheng Feng, Qingyan Bo, Hugh A Coleman, Jean Eric Charoin, Mingfen Zhu, Jim Xiao, Yuyan Jin
Further Evaluation of Coproporphyrins as Clinical Endogenous Markers for OATP1B. Journal of clinical pharmacology 61 (8) (2021)
Xiaojie Wu, Sheng Feng, Jing Zhang, Wenhong Zhang, Yuchen Zhang, Mingfen Zhu, Miriam Triyatni, Na Zhao, Qingyan Bo, Yuyan Jin
Evaluation of the safety, tolerability, and pharmacokinetics of RO7049389 in healthy Chinese volunteers. Clinical and translational science (2021)
Sheng Feng, Edward Gane, Christian Schwabe, Mingfen Zhu, Miriam Triyatni, Julian Zhou, Qingyan Bo, Yuyan Jin
A Five-in-One First-in-Human Study To Assess Safety, Tolerability, and Pharmacokinetics of RO7049389, an Inhibitor of Hepatitis B Virus Capsid Assembly, after Single and Multiple Ascending Doses in Healthy Participants. Antimicrobial agents and chemotherapy 64 (11) (2020)